KRYS Company Profile and Key Details

Q: Who are the executives of KRYS?

Ms. Gloria LinAccounting Mang.Dr. Andrew C. OrthExecutive Vice President & Chief Commercial OfficerMr. Josh SuskinDirector of HR & OperationsMs. Katherine TuminelloHR & Office Mang.Mr. David GlynnGen. Counsel, Commercial & ComplianceMr. John KarakkalVice President of North American Sales & MarketingDr. Andreas C. OrthExecutive Vice President & Chief Commercial OfficerMr. Krish S. Krishnan M.B.A., M.S.Founder, Chairman, Pres & Chief Executive OfficerMs. Suma M. KrishnanFounder, Chief Operating Officer, Pres of R&D and DirectorMr. John GarciaSenior Vice President of U.S. Bus. Sales & OperationsMs. Meg DodgeVice President of Investor Relations & Corporation CommunicationsMs. Kathryn A. RomanoExecutive Vice President & Chief Accounting OfficerMr. Ram KamineniSenior Vice President of CMC & Technical OperationsMr. Laurent GouxSenior Vice President & GM of Europe

NASDAQ : KRYS

Krystal Biotech

$267.64

-1.49-0.55%

At Close 4:00 PM

69.18

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Krystal Biotech, Inc. (KRYS) stock declined over -0.55%, trading at $267.64 on NASDAQ, down from the previous close of $269.13. The stock opened at $265.43, fluctuating between $265.29 and $273.67 in the recent session.

Stock Snapshot

269.13

Prev. Close

7.76B

Market Cap

265.29

Day Low

40.07

P/E Ratio

6.68

EPS (TTM)

-3.57

Cash Flow per Share

265.43

Open

29M

Number of Shares

273.67

Day High

79.4%

Free Float in %

27.64

Book Value

284.69K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	265.43	274.06	265.29	267.64	284.69K
Feb 04, 2026	281.32	282.33	258.34	269.13	434.5K
Feb 03, 2026	282.27	286.52	273.23	279.57	150.13K
Feb 02, 2026	276.58	285.97	276.05	282.27	219K
Jan 30, 2026	281.92	282.47	274.89	279.24	262.2K
Jan 29, 2026	273.03	283.61	273.03	279.34	217.88K
Jan 28, 2026	278.19	279.62	272.15	272.91	256.74K
Jan 27, 2026	278.75	281.28	275.07	277.36	167.85K
Jan 26, 2026	279.47	281.00	275.00	278.75	155.6K
Jan 23, 2026	289.98	294.64	280.64	281.53	310.76K
Jan 22, 2026	286.20	292.49	286.20	289.13	211.91K
Jan 21, 2026	274.58	286.28	271.70	286.00	243.11K
Jan 20, 2026	280.02	282.20	271.52	274.81	428.58K
Jan 16, 2026	284.17	289.78	282.00	285.04	264.35K
Jan 15, 2026	295.00	295.00	279.56	282.01	285.77K
Jan 14, 2026	292.40	295.98	287.57	291.79	319.68K
Jan 13, 2026	273.92	292.90	266.65	291.93	510.01K
Jan 12, 2026	260.64	274.40	257.00	272.13	462.34K
Jan 09, 2026	254.51	267.48	252.92	261.41	349.84K
Jan 08, 2026	249.51	255.07	245.99	248.91	421.04K

Contact Details

Pittsburgh, PA 15203

United States

https://www.krystalbio.com 412 586 5830

About Company

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Stock Peers

ARGX

-30.56-3.59%

argenx SE$820.31 REGN

-8.43-1.09%

Regeneron Pharmaceuticals, Inc.$766.63 UTHR

-3.66-0.76%

United Therapeutics Corporation$478.93 MDGL

-15.19-3.17%

Madrigal Pharmaceuticals, Inc.$463.42 VRTX

-11.71-2.49%

Vertex Pharmaceuticals Incorporated$458.81 ALNY

-20.72-5.89%

Alnylam Pharmaceuticals, Inc.$331.24 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

2.28+0.75%

Praxis Precision Medicines, Inc.$305.62 SGEN

-0.16-0.07%

Seagen Inc.$228.74 CDTX

Cidara Therapeutics, Inc.$221.38

Company Overview

Krystal Biotech, Inc. (NASDAQ:KRYS) closed at $267.64 USD, losing -$1.49 (-0.55%) from the previous close of $269.13. The stock is currently mid-range between its 52-week high and low $122.80 and $295.98. With a market capitalization of about $7.76 billion, Krystal Biotech, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.48). Key stats such as the average daily volume over the past year has been around 291.01 thousand shares, in line with its 52-week average. Headquartered in Pittsburgh, PA, Krystal Biotech, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Krish S. Krishnan, the company employs approximately 275 people and listed since September 20, 2017. Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -3.57%, SMA50 5.73%, SMA200 47.31%). The stock’s 14-day RSI is 49.34 (neutral), while the ATR of 11.02 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -9.57% below its high and over 117.95% above its low. Average 10-day trading volume of 238.73 thousand shares is below the 3-month average of 287.74 thousand, indicating normal recent market interest.

Valuation Metrics

Krystal Biotech, Inc. trades at a P/E ratio of 39.04, slightly above the S&P 500 average, with a price-to-sales ratio of 20.84 and a price-to-book ratio of 6.82 trading at moderately above to book value. The P/FCF stands at 46.97, also above market averages.

Dividend & Fair Value

Krystal Biotech, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $288.44. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 50.82% annually over the next five years. The latest quarter delivered EPS of $2.66. The next quarter is forecast at $1.55. Next year's EPS is expected at $79.12. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 23 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $336.00 to $155.00. The high target offers 25.54% upside. The low target suggests -42.09% downside. The mean target is $240.24. This offers -10.24% upside. Krystal Biotech, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 03, 2025, missed forecasts by 137.5%. The prior quarter beat by 19.44%. Over the last six quarters, Apple has recorded several small beats. These include 5.0% in August 05, 2024.

Shareholding & Insider Activity

Krystal Biotech, Inc. has 28.94 million shares outstanding. The public float is 22.98 million shares, elevated short interest at 19.67% of float. This equals 3.40 million shares. The short ratio is 11.72 days. Institutional investors hold 114.52% of the float. Insiders own 11.86%. Krishnan Krish S holds 1.41 million shares, Krishnan Suma has 1.41 million shares and JANNEY DANIEL has 107.36 thousand shares. Over the past six months, insider transactions show net selling. They sold 400.00 shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Krystal Biotech generated $50.70M in revenue, or $1.83 per share. Gross margin was 84.02%, operating margin -191.77%, and net profit margin 21.56%. Returns are modest, with ROA at 1.34% and ROE at 1.40%.
On valuation metrics, Krystal Biotech trades at a P/E of 39.04, P/S of 20.84 and P/B of 6.82. The current ratio is 10.14 and quick ratio is 9.73. Operationally, the company’s inventory turnover is 0.61 and cash conversion cycle is 695.54 days. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of 18.53.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Krystal Biotech posted revenue of $50.70M, down slightly from $0.00 in the prior quarter. Gross profit was $42.60M (margin 84.02%). Operating income was - $97.23M (margin -191.8%). Net income was$10.93M (EPS $0.40).
The company ended the quarter with $532.18M in cash and short-term investments, a total debt of $8.09M, and net debt of - $350.23M. Total assets were $818.36M, with equity of $778.64M. Financials further reflected weakness, with operating cash flow of - $88.80M, free cash flow of - $100.60M, and capital expenditures of - $11.80M.

Price Forecast & Outlook

Our AI price prediction model suggests that Krystal Biotech, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.41%, with price expected at $287.48 by February 18, 2026, within a range of $275.06 to $299.40 3-Month Outlook: Projected rise of 42.84%, reaching $382.29 by May 05, 2026, with a range of $378.35 to $386.24. 1-Year Outlook: Projected gain of 17.46%, with price at $314.38 by February 04, 2027, within a range of $302.50 to $324.40.

Key Takeaways

Krystal Biotech, Inc. (NASDAQ:KRYS) shares are up 11.47% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Krystal Biotech, Inc. trading at a premium to the broader market with a P/E of 39.04. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $187.16, suggesting -30.07% downside. Our AI forecast model points to short-term strength (7.41% over two weeks), a medium-term rise (42.84% over three months), and a longer-term gain (17.46% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Krystal Biotech, Inc. (KRYS) stock price?

Krystal Biotech, Inc. (NASDAQ: KRYS) stock price is $267.64 in the last trading session. During the trading session, KRYS stock reached the peak price of $273.67 while $265.29 was the lowest point it dropped to. The percentage change in KRYS stock occurred in the recent session was -0.55% while the dollar amount for the price change in KRYS stock was - $1.49.

KRYS's industry and sector of operation?

The NASDAQ listed KRYS is part of Biotechnology industry that operates in the broader Healthcare sector. Krystal Biotech, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of KRYS?

Ms. Gloria Lin
Accounting Mang.
Dr. Andrew C. Orth
Executive Vice President & Chief Commercial Officer
Mr. Josh Suskin
Director of HR & Operations
Ms. Katherine Tuminello
HR & Office Mang.
Mr. David Glynn
Gen. Counsel, Commercial & Compliance
Mr. John Karakkal
Vice President of North American Sales & Marketing
Dr. Andreas C. Orth
Executive Vice President & Chief Commercial Officer
Mr. Krish S. Krishnan M.B.A., M.S.
Founder, Chairman, Pres & Chief Executive Officer
Ms. Suma M. Krishnan
Founder, Chief Operating Officer, Pres of R&D and Director
Mr. John Garcia
Senior Vice President of U.S. Bus. Sales & Operations
Ms. Meg Dodge
Vice President of Investor Relations & Corporation Communications
Ms. Kathryn A. Romano
Executive Vice President & Chief Accounting Officer
Mr. Ram Kamineni
Senior Vice President of CMC & Technical Operations
Mr. Laurent Goux
Senior Vice President & GM of Europe

How KRYS did perform over past 52-week?

KRYS's closing price is 117.95% higher than its 52-week low of $122.80 where as its distance from 52-week high of $295.98 is -9.57%.

How many employees does KRYS have?

Number of KRYS employees currently stands at 275.

Link for KRYS official website?

Official Website of KRYS is: https://www.krystalbio.com

How do I contact KRYS?

KRYS could be contacted at phone 412 586 5830 and can also be accessed through its website. KRYS operates from 2100 Wharton Street, Pittsburgh, PA 15203, United States.

How many shares of KRYS are traded daily?

KRYS stock volume for the day was 284.69K shares. The average number of KRYS shares traded daily for last 3 months was 291.01K.

What is the market cap of KRYS currently?

The market value of KRYS currently stands at $7.76B with its latest stock price at $267.64 and 29M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	275
Beta	0.46
Sales or Revenue	$50.70M
5Y Sales Change%	19.367%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

KRYS Company Profile and Key Details

Krystal Biotech

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Shareholding & Insider Activity

Earnings & Analyst Outlook

Key Takeaways

Price Forecast & Outlook

Valuation Metrics